PREVIEW: Abbvie Inc (ABBV) earnings due 02/Feb at 12:40GMT/07:40EST

Abbvie Inc (ABBV) Q4 2021 (USD): EPS (exp. 3.29/2.10 GAAP), Revenue (exp. 14.97bln)

KEY PHARMA SALES:

• Humira/Adalimumab: (exp. 5.4bln)
• Imbruvica: (exp. 1.45bln)
• Skyrizi /Bi-655066/Risankizumab: (exp. 0.87bln)
• Botox/Botox Cosmetic: (exp. 0.575bln)
• ABT 494/Upadacitinib/Rinvoq: (exp. 0.53bln)

DIVIDEND:

• Qtrly Dividend: (exp. 1.41)
• FY Dividend: (exp. 5.23)

EPS GUIDANCE:

• Q1 2022 EPS View: (exp. 3.22/2.11 GAAP)
• FY 2022 EPS View: (exp. 13.99/9.15 GAAP)

REVENUE GUIDANCE:

• Q1 2022 Revenue View: (exp. 13.87bln)
• FY 2022 Revenue View: (exp. 59.81bln)

INDEX WEIGHT:

• 0.6% SPX weight
• Sector/Industry: Health Care/Biotechnology

BROKER RATING:

• Avg Rating: 'Buy'
• Avg Price Target: USD 142.40
• Price Target Changes (last 30 days): 7 upward vs 3 downward